ECI Vaccine IX 2024 -- Self-amplifying RNA (sa mRNA) formulated in lipid nanoparticles (LNPs) is a novel vaccine modality and is being used to develop a Marburg Virus vaccine comprising the Glycoprotein (MARV) sa mRNA. Imidazoquinoline TLR-7 agonists have been encapsulated with the MARV sa mRNA-LNP with the aim of testing for adjuvancy in vivo.

ECI Vaccine IX 2024 -- Self-amplifying RNA (sa mRNA) formulated in lipid nanoparticles (LNPs) is a novel vaccine modality and is being used to develop a Marburg Virus vaccine comprising the Glycoprotein (MARV) sa mRNA.

ECI Vaccine IX 2024 -- Self-amplifying RNA (sa mRNA) formulated in lipid nanoparticles (LNPs) is a novel vaccine modality and is being used to develop a Marburg Virus vaccine comprising the Glycoprotein (MARV) sa mRNA.

OBN & University of Reading Pain Research and Therapeutics Conference 2024 -- Drug abuse liability assessment is required for drugs (parent or major metabolite) that penetrate the brain, regardless of the therapeutic indication.

ALL is more commonly found in young children but also arises in older adults. Children have a >80% cure rate while adults only have a 20-30% cure rate. A similar disease is chronic lymphocytic leukemia (CLL) which is generally diagnosed in older adults.

Even though a number of advances have been made in cancer treatments and surgical approaches, little progress in ovarian cancer therapy has provided a meaningful impact on this patient population.

Researchers use preclinical mouse modeling of lymphoma to explore novel combination strategies of conventional chemotherapy or radiation and immunomodulatory agents.

Contact the preclinical oncology scientific team to learn more. 

Most prostate cancers are adenocarcinomas that develop from the gland cells that produce seminal fluid.

New oncology drugs only have a 3.4% success rate once making it from Phase I clinical trials to FDA approval. This is the lowest success rate among the 21 major disease indications.1 This poor success rate leaves everyone, from the patients to the benchtop scientists, questioning the validity of the models and the resulting data.